Whitehawk Therapeutics appointed Vijay Iyengar to its board and granted Options to purchase 76,080 common shares. The appointment adds oncology, medical affairs, strategy and business-development experience to the board, while the director compensation policy provides a $40,000 annual retainer for non-employee directors.

Key Highlights

  • Vijay Iyengar’s Class III director term runs through Whitehawk Therapeutics’ 2029 annual meeting.
  • Non-employee directors receive a $40,000 annual cash retainer under the company’s compensation policy.
  • Iyengar previously held senior Leadership roles at Incyte and Novartis and earned degrees from Stanford University and Harvard Medical School.

Whitehawk Therapeutics, Inc. (NASDAQ: WHWK) added Vijay Iyengar, M.D. To its board effective September 9, 2026, filling a newly created seat and granting him options to purchase 76,080 shares of common stock. The Class III director will serve until the 2029 annual meeting of stockholders, subject to earlier resignation, death or removal.

Board Seat Carries $40,000 Retainer

The board expanded its authorized director count and appointed Iyengar as a non-employee director. Under Whitehawk’s outside director compensation policy, non-employee directors receive a $40,000 base annual retainer. Iyengar’s initial option award was granted on September 9, 2026, and will vest monthly on a ratable basis over the vesting period, subject to his continued service. Whitehawk also entered into an indemnification agreement with him in the same form used for its other directors. The company said Iyengar has no family relationship with any director or executive officer and was not appointed under an arrangement with another person. It also said he has not engaged in a related-party transaction reportable under the applicable rules.

Former Incyte Executive Brings Oncology Experience

Iyengar previously served as Executive Vice President of Global Medical Affairs, Product and Partnership Strategy at Incyte (NASDAQ: INCY) and earlier held its global strategy and corporate development leadership role. During his senior leadership at Incyte, annual Revenue grew from approximately $1B to more than $4B. Whitehawk said his industry background and life sciences experience supported his appointment, while his education includes a biology degree from Stanford University and a medical degree from Harvard Medical School.